Thursday, February 28, 2019

Novavax downgraded to Underweight from Overweight at JPMorgan

JPMorgan analyst Eric Joseph double downgraded Novavax to Underweight from Overweight saying he sees a “limited path forward” following the on RexVax Phase 3 failure.
at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.